company background image
6634

Sinew Pharma TPEX:6634 Stock Report

Last Price

NT$79.80

Market Cap

NT$5.5b

7D

-2.9%

1Y

-0.7%

Updated

15 May, 2022

Data

Company Financials
6634 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

6634 Stock Overview

Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases.

Sinew Pharma Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Sinew Pharma
Historical stock prices
Current Share PriceNT$79.80
52 Week HighNT$99.00
52 Week LowNT$62.10
Beta1.52
1 Month Change-5.00%
3 Month Change-0.50%
1 Year Change-0.75%
3 Year Change179.90%
5 Year Changen/a
Change since IPO60.24%

Recent News & Updates

Mar 11
Companies Like Sinew Pharma (GTSM:6634) Can Afford To Invest In Growth

Companies Like Sinew Pharma (GTSM:6634) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Sinew Pharma ( GTSM:6634...

Nov 25
Sinew Pharma (GTSM:6634) Is In A Strong Position To Grow Its Business

Sinew Pharma (GTSM:6634) Is In A Strong Position To Grow Its Business

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Sinew Pharma...

Shareholder Returns

6634TW PharmaceuticalsTW Market
7D-2.9%-4.6%-3.4%
1Y-0.7%3.0%0.7%

Return vs Industry: 6634 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.

Return vs Market: 6634 underperformed the TW Market which returned 0.7% over the past year.

Price Volatility

Is 6634's price volatile compared to industry and market?
6634 volatility
6634 Average Weekly Movement5.6%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6634 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 6634's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201333Kaimin Chuhttps://www.sinewpharma.com

Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States.

Sinew Pharma Fundamentals Summary

How do Sinew Pharma's earnings and revenue compare to its market cap?
6634 fundamental statistics
Market CapNT$5.51b
Earnings (TTM)-NT$91.57m
Revenue (TTM)NT$6.23m

884.7x

P/S Ratio

-60.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6634 income statement (TTM)
RevenueNT$6.23m
Cost of RevenueNT$1.14m
Gross ProfitNT$5.09m
Other ExpensesNT$96.67m
Earnings-NT$91.57m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.33
Gross Margin81.75%
Net Profit Margin-1,470.14%
Debt/Equity Ratio0%

How did 6634 perform over the long term?

See historical performance and comparison

Valuation

Is Sinew Pharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


3.51x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6634's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6634's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 6634 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 6634 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6634's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6634 is overvalued based on its PB Ratio (3.5x) compared to the TW Pharmaceuticals industry average (2x).


Future Growth

How is Sinew Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


50.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sinew Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Sinew Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-2.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6634 is currently unprofitable.

Growing Profit Margin: 6634 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6634 is unprofitable, and losses have increased over the past 5 years at a rate of 2.8% per year.

Accelerating Growth: Unable to compare 6634's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6634 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).


Return on Equity

High ROE: 6634 has a negative Return on Equity (-5.84%), as it is currently unprofitable.


Financial Health

How is Sinew Pharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6634's short term assets (NT$1.5B) exceed its short term liabilities (NT$15.1M).

Long Term Liabilities: 6634's short term assets (NT$1.5B) exceed its long term liabilities (NT$850.0K).


Debt to Equity History and Analysis

Debt Level: 6634 is debt free.

Reducing Debt: 6634 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6634 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6634 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 4.1% each year


Dividend

What is Sinew Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6634's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6634's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6634's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6634's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6634 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Kaimin Chu

no data

Tenure

Dr. Kaimin Chu MD, PhD, serves as the Chairman & Chief Executive Officer at Sinew Pharma Inc. Dr. Chu served as Director of the Clinical Research Center and Director of Cardiology at the Tri-Service Genera...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.1%.


Top Shareholders

Company Information

Sinew Pharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sinew Pharma Inc.
  • Ticker: 6634
  • Exchange: TPEX
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$5.510b
  • Shares outstanding: 69.05m
  • Website: https://www.sinewpharma.com

Number of Employees


Location

  • Sinew Pharma Inc.
  • C516, Building C
  • No. 99, Ln. 130
  • Taipei
  • 11571
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.